Navigation Links
Leading Cardiologist Joins Ontario Research Firm to Conduct New Clinical Trial on the Effect of Pantethine on Cholesterol Levels

Dr. John A. Rumberger and KGK Synergize Will Study Ingredient's

Impact on North Americans

NEW YORK, Sept. 25 /PRNewswire/ -- Daiichi Fine Chemical Co., Ltd. of Japan today announced that it has selected world-renowned Cardiologist Dr. John A. Rumberger and the Contract Research Division of KGK Synergize Inc. to launch a new clinical trial to investigate the effect of Pantethine as a dietary supplement for lipid management and the reduction of cardiovascular risk factors in the North American population.

The randomized, double-blind placebo controlled study will be conducted in two North American locations by Ontario-based KGK under the direction of Dr. Dale Wilson, KGK medical director and principal investigator for the study.

An internationally recognized specialist in preventive cardiology, Rumberger currently is director of cardiac imaging at the Princeton (N.J.) Longevity Center, clinical professor of medicine at Ohio State University and former professor of medicine at the Mayo Clinic. He also is author of 'The Way Diet' which provides information about optimal diet, supplementation, exercise and stress management in preventing heart disease. He will offer consultation on protocol design and comment on the findings of the clinical trial.

The study design process started last month, study subjects at low to moderate risk levels of cardiovascular disease will be treated over a 16-week period, and results are expected by the third quarter of 2009.

Daiichi Fine Chemical, sponsor of the study, is the world's leading supplier of pantothenic acid (vitamin B5) and its derivatives, including pantethine, marketed under the brand name Pantesin(R). Sold in Japan for more than 35 years, Pantesin has been available as a dietary supplement in the United States since 1992. Although Pantesin's effectiveness in safely lowering cholesterol levels has been documented in more than 30 clinical studies, the new study will be the most expansive ever conducted using North American subjects.

"Maintaining an optimal balance among LDL, HDL, and triglycerides is more important than simply lowering cholesterol and key to cardiovascular health," Rumberger said. "A low-fat and modified carbohydrate diet, exercise and regular consumption of dietary supplements formulated with scientifically proven, high quality ingredients can help individuals achieve a healthy blood lipid profile.

"A large body of research points to Pantethine's effectiveness in Asian and Western European populations, where oral administration of Pantethine has consistently shown an ability to favorably impact a variety of risk factors in people with hypercholesterolemia, arteriosclerosis and diabetes. The aim of the current trial is to confirm these results in a clinical setting in North America where cardiovascular disease is the leading cause of death."

Founded in 1997 by three scientists associated with the Centre for Human Nutrition at The University of Western Ontario, KGK maintains a global reputation for uncompromising science focused on nutraceutical, biotechnology and pharmaceutical product research.

"Our team of research experts is devoted to discovering the unique properties inherent in natural products that enhance and promote a healthy lifestyle," said KGK President and Chief Executive Officer Najla Guthrie. "Our in-house lab and clinic along with our location at a leading

scientific and medical research center ensure timely and conclusive research results overseen by leading physicians in the area of study."

Daiichi Fine Chemical is a global leader in researching the use of pantethine. By commissioning this new clinical trial, Daiichi signals its continued support of research that takes into account lifestyle changes and breakthrough discoveries that may impact the role Pantethine can play in enhancing cardiovascular health.

About Daiichi Fine Chemical

Daiichi Fine Chemical Co. Ltd., is the world's largest supplier of the cholesterol-management agent pantethine, a derivative of vitamin B5, which it markets under the brand name Pantesin(R). Daiichi Fine Chemical has a reputation of strict pharmaceutical GMP standards at the firm's vertically integrated operation in Japan which are applied to Pantesin(R). Kyowa Hakko Kogyo Co., Ltd., Japan acquired all shares of Daiichi Fine Chemical from Daiichi-Sankyo Co., Ltd. in 2007. As a wholly owned subsidiary in Kyowa's bio-chemical business, Daiichi Fine Chemical continues to supply vitamin B5 of highest quality standards. For more information visit

About KGK Synergize, Inc.

Created in 1997 by three experienced nutritional scientists from University of Western Ontario to facilitate commercialization of research and development findings, KGK Synergize, Inc. provides contract research services to health nutrition, biotechnology and pharmaceutical industries. In addition to providing contract research services, KGK's Product Development Division brings new and innovative natural health products to the point where they are ready to be manufactured and marketed. For more information visit

SOURCE Daiichi Fine Chemical Co., Ltd. of Japan
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Leading Healthcare System Decreases MRSA Infection Rate by 53 Percent - Offers Protocol & Educational Materials Free of Charge to Other Organizations
2. Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First Real World, All Comers Clinical Study
3. FDA Lifts Clinical Hold on Gentas Tesetaxel, a Leading Oral Taxane
4. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
5. Leading Immunologists Convene in Boston
6. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
7. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
8. Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist
9. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
10. Leading AIDS Groups Turn Up The Heat on 08 Presidential Candidates
11. Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection
Post Your Comments:
(Date:10/12/2015)... Given the intricacy of the anatomy and physiology of ... drug effectively to a specific ocular site. Several barriers have ... include dilution of a drug by tears, clearance of a ... issues with respect to the cornea, sclera and choroid. Approximately ... due to the aforementioned barriers. --> Given ...
(Date:10/12/2015)... 12, 2015  Former White House Spokesman, and Drug Czar ... House Narcotics Committee, Robert Weiner , and Policy Analyst ... two emphasize that this is now a potential bipartisan campaign ... Jeb Bush , Carly Fiorina to Rand ... federal statistics, which they call "a shocker: 23 million need ...
(Date:10/12/2015)... 2015  Luminex Corporation (NASDAQ: LMNX ) today announced ... ended September 30, 2015 on Monday, November 2, 2015. A ... the close of trading. --> ... discuss the operating highlights and financial results for the third ... 4:30 p.m. Eastern time. . Simply ...
Breaking Medicine Technology:
(Date:10/13/2015)... CA (PRWEB) , ... October 13, 2015 , ... According ... Care, a recent study has shown that women who successfully lose weight with a ... in the United States each year. The article notes that anywhere from 40 to ...
(Date:10/13/2015)... ... 13, 2015 , ... Altec Products, Inc., the leader in ... Dynamics AXUG, GPUG and NAVUG Summits to take place the week of October ... user conferences designed and led by users to provide attendees with a unique ...
(Date:10/13/2015)... ... 13, 2015 , ... Element Blue ™, a leading ... company, RightSensor™ LLC, an Internet of Things (IoT) hardware supplier that delivers custom ... approach for customers requiring sensor hardware for critical data environments. , RightSensor™, working ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... private messaging application, announced today a significant contract that will provide its award-winning ... plans to build on the growing success of its Relay program, IBX Wire™, ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... e-con Systems ... solutions, today announced See3CAM_CU40, the industry’s first RGB-IR pixel format camera with ... a new member of e-con’s See3CAM family of UVC USB 3.0 cameras, is based ...
Breaking Medicine News(10 mins):